Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 2CL Protease

View/ Open
Issue Date
2016-03-10Author
Damalanka, Vishnu C.
Kim, Yunjeong
Alliston, Kevin R.
Weerawarna, Pathum M.
Kankanamalage, Anushka C. Galasiti
Lushington, Gerald H.
Mehzabeen, Nurjahan
Battaile, Kevin P.
Lovell, Scott
Chang, Kyeong-Ok
Groutas, William C.
Publisher
American Chemical Society
Type
Article
Article Version
Scholarly/refereed, author accepted manuscript
Rights
This document is the Accepted Manuscript version of a Published Work that appeared in final form in the Journal of Medicinal Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see http://dx.doi.org/10.1021/acs.jmedchem.5b01464.
Metadata
Show full item recordAbstract
Human noroviruses are the primary causative agents of acute gastroenteritis and a pressing public health burden worldwide. There are currently no vaccines or small molecule therapeutics available for the treatment or prophylaxis of norovirus infections. Norovirus 3CL protease plays a vital role in viral replication by generating structural and nonstructural proteins via the cleavage of the viral polyprotein. Thus, molecules that inhibit the viral protease may have potential therapeutic value. We describe herein the structure-based design, synthesis, and in vitro and cell-based evaluation of the first class of oxadiazole-based, permeable macrocyclic inhibitors of norovirus 3CL protease.
Collections
Citation
Damalanka, V. C., Kim, Y., Alliston, K. R., Weerawarna, P. M., Galasiti Kankanamalage, A. C., Lushington, G. H., … Groutas, W. C. (2016). Oxadiazole-Based Cell Permeable Macrocyclic Transition State Inhibitors of Norovirus 3CL Protease. Journal of Medicinal Chemistry, 59(5), 1899–1913. http://doi.org/10.1021/acs.jmedchem.5b01464
Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.